{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qu S"],"funding":["Intramural NIH HHS","National Cancer Institute"],"pagination":["141-153"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8692365"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Introduction</h4>A new molecular subtype classification was recently proposed for SCLC. It is necessary to validate it in primary SCLC tumors by immunohistochemical (IHC) staining and define its clinical relevance.<h4>Methods</h4>We used IHC to assess four subtype markers (ASCL1, NEUROD1, POU2F3, and YAP1) in 194 cores from 146 primary SCLC tumors. The profiles of tumor-associated CD3<sup>+</sup> and CD8<sup>+</sup> T-cells, MYC paralogs, SLFN11, and SYP were compared among different subtypes. Validation was performed using publicly available RNA sequencing data of SCLC.<h4>Results</h4>ASCL1, NEUROD1, POU2F3, and YAP1 were the dominant molecular subtypes in 78.2%, 5.6%, 7%, and 2.8% of the tumors, respectively; 6.3% of the tumors were negative for all four subtype markers. Notably, thr"],"journal":["Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"],"pubmed_title":["Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers."],"pmcid":["PMC8692365"],"funding_grant_id":["BC006161","ZIA BC011787","Z01 BC006161","ZIA BC011839"],"pubmed_authors":["Schrump DS","Qu S","Pommier Y","Thomas A","Chen H","Miettinen MM","Fetsch P"],"additional_accession":[]},"is_claimable":false,"name":"Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.","description":"<h4>Introduction</h4>A new molecular subtype classification was recently proposed for SCLC. It is necessary to validate it in primary SCLC tumors by immunohistochemical (IHC) staining and define its clinical relevance.<h4>Methods</h4>We used IHC to assess four subtype markers (ASCL1, NEUROD1, POU2F3, and YAP1) in 194 cores from 146 primary SCLC tumors. The profiles of tumor-associated CD3<sup>+</sup> and CD8<sup>+</sup> T-cells, MYC paralogs, SLFN11, and SYP were compared among different subtypes. Validation was performed using publicly available RNA sequencing data of SCLC.<h4>Results</h4>ASCL1, NEUROD1, POU2F3, and YAP1 were the dominant molecular subtypes in 78.2%, 5.6%, 7%, and 2.8% of the tumors, respectively; 6.3% of the tumors were negative for all four subtype markers. Notably, thr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T00:23:28.229Z","creation":"2024-11-20T04:35:52.467Z"},"accession":"S-EPMC8692365","cross_references":{"pubmed":["34534680"],"doi":["10.1016/j.jtho.2021.08.763"]}}